16 Services from clinicalintelpulse.theaslangroupllc.com

Scans the global clinical trial pipeline for any disease, returning active Phase 2/3 trial counts, sponsor landscape, geographic distribution, mechanism breakdown, and pipeline density across 400,000+ trials.

Retrieves a comprehensive deep-dive profile of a specific ClinicalTrials.gov study by NCT ID, including trial design, endpoints, enrollment, sponsor, and publications.

Looks up clinical trial status and details by NCT ID or searches trials by condition/sponsor with phase and status filters via the official ClinicalTrials.gov v2 API

Finds actively recruiting clinical trials for a given disease or diagnosis, returning plain-language summaries, eligibility criteria, country filter, contacts, and how to apply from 400,000+ ClinicalTrials.gov studies.

Cross-references FDA-approved drug interaction and contraindication data for two or more drugs, flagging interactions in plain language with severity ratings and recommended actions.

Checks the FDA enforcement database for active and past recalls of a specific drug, explains the recall class in plain language, and provides guidance on next steps.

Returns the drug mechanism-of-action and molecular target landscape for a disease, including targets in active trials, approved agents by MOA, crowded vs. novel mechanisms, first-in-class openings, and key publications.

Returns a comprehensive competitive drug pipeline landscape for a given disease, including Phase 2/3 trial map, mechanism-of-action coverage, approved drugs, PDUFA calendar, M&A activity, opportunity gaps, and investment thesis.

Returns a structured failure taxonomy for Phase 2/3 clinical trials in a disease area, including failure reasons, percentages, phase-transition success rates, and design lessons.

Returns a deterministic, LLM-free preview of biotech M&A deal-signal candidates for a disease area — Phase 2/3 trial counts and industry-sponsored asset lists sourced directly from ClinicalTrials.gov.

Returns the global clinical trial landscape for a disease, including geographic distribution across WHO ICTRP registries, regulatory pathways, access gaps, and unmet need by region.

Returns FDA/EMA approval probability scores and PDUFA calendar for Phase 3 drugs in a given disease area, including mechanism of action, trial results, and historical phase-3 success rates.

Returns a deterministic preview of the clinical trial pipeline for a disease — Phase 2/3 trial counts, sponsor rollup, trial-status breakdown, and a sample of trials from ClinicalTrials.gov — with no LLM synthesis.

Returns a comprehensive drug pipeline intelligence report for a given pharma/biotech sponsor — covering pipeline phases, therapeutic areas, FDA approval history, partnerships, competitive positioning, and investment catalysts.

Returns a plain-language explainer for any prescription or OTC drug from its FDA-approved label, including what it treats, dosing, boxed warnings, contraindications, side effects, and pregnancy notes.

Returns M&A and licensing deal signals for clinical-stage Phase 2/3 drug assets — identifying acquisition targets, deal comparables, transaction multiples, and estimated deal values worldwide.